KNSA - NASDAQ
Kiniksa Pharmaceuticals, Ltd.
$47.85
+0.073%Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
At a Glance
Live SnapshotKiniksa Pharmaceuticals, Ltd. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Kiniksa Pharmaceuticals, Ltd. Income Statement
KNSA • NASDAQ
| Kiniksa Pharmaceuticals, Ltd. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
677.6M | 423.2M | 270.3M | 220.2M | 38.5M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||
(307.4M) | (60.9M) | (56.5M) | (22.9M) | (9.1M) | (3.8M) | (3.3M) | (286K) | (28K) | (22K) | |
370.2M | 362.3M | 213.7M | 197.3M | 29.4M | -3.8M | -3.3M | -286K | -28K | -22K | |
OPERATING INCOME | ||||||||||
(292.9M) | (407.9M) | (238.9M) | (187.5M) | (186.1M) | (153.6M) | (166.7M) | (108.2M) | (65.4M) | (24M) | |
(196.3M) | (168M) | (129.4M) | (98M) | (85.9M) | (43.9M) | (33.8M) | (21.6M) | (9M) | (6.6M) | |
(96.9M) | (111.6M) | (76.1M) | (65.5M) | (99.3M) | (109.6M) | (132.9M) | (86.6M) | (56.4M) | (17.4M) | |
77.2M | -45.6M | -25.2M | 9.8M | -156.6M | -157.4M | -170M | -108.2M | -65.4M | -24M | |
PRE-TAX INCOME | ||||||||||
0.0 | 9.5M | 8.5M | 1.3M | 97K | 1.1M | 6M | 0.0 | 0.0 | 0.0 | |
(0.0) | (128.3M) | (33.4M) | (24.1M) | (835K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
11.6M | 9.5M | 8.5M | 1.3M | 97K | 1.1M | 6M | 4.7M | 529K | 65K | |
88.9M | -36.2M | -16.7M | 11M | -156.5M | -156.2M | -163.9M | -103.4M | -64.9M | -23.9M | |
NET INCOME | ||||||||||
(29.9M) | (7M) | -30.7M | -172.3M | (1.4M) | (5.2M) | -2M | -214K | (2K) | (36K) | |
59M | -43.2M | 14.1M | 183.4M | -157.9M | -161.4M | -161.9M | -103.2M | -64.9M | -24M |
SEC Filings
KNSA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 26, 2026 | May 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 01, 2026 | April 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 28, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 24, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 14, 2026 | January 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 |
Related Guides
Continue your KNSA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.